- Poster presentation
- Open Access
IMPACT OF TRIALS ON CLINICAL PRACTICE: INTERVENTIONS IN SEPTIC SHOCK PATIENTS BETWEEN 2005 AND 2013
Intensive Care Medicine Experimental volume 3, Article number: A430 (2015)
Evidence based medicine [EBM] at bedside, a key healthcare quality measure, refers to the compendium for delivering optimum clinical care by balancing benefit-harm-costs. EBM involves appraisal, interpretation and implementation with adoption of beneficial interventions and de-adoption of interventions with potential harm.
Our hypothesis from Niven et al  where the reversal of intervention effect was not associated with timely de-adoption, is that for a rapid change in clinical practice perceived cost [monetary or clinical harm] attributable to the intervention must be high.
Tight glucose control [TGC] and corticosteroids are examples of nonproprietary and recombinant Activated protein C [rt-APC] an example of proprietary intervention with reversal of effect between publications, from benefit to harm. All three interventions were part of the Surviving Sepsis Campaign [SSC] EBM .
We explored the impact of reversal of intervention effect in septic shock trials on the adoption - de-adoption cycle of these three interventions; hypothesis being visible 'cost' influences EBM.
Guy's and St. Thomas' NHS Foundation Trust (London, England) is a 1,150-bed, University hospital with closed mixed medical and surgical ICUs and an early adopter of the SSC. Trained data collectors prospectively recorded all ICU admissions with severe sepsis/septic shock (SS) [2005 to 2013] into the SSC database. We report the adoption - de-adoption cycle of the interventions with effect reversal [rt-APC, corticosteroids, TGC] or unchanged (Antibiotics < 3hours; lactate measurement < 6 hours and lung protective ventilation [LPV]) over this period, relative to seminal publications for each intervention in septic shock patients.  As an on-going hospital approved audit since inception, informed consent was waived. Data analysis was performed using Stata v13.1 (StataCorp, LP).
N = 1,150 septic shock admissions. Compliance with intervention effect unchanged [antibiotics, lactate measurement and LPV] was high [Figure 1a]. Publication of CORTICUS trial reduced steroid use, whereas with the publication of PROWESS-SHOCK  study alongside drug withdrawal stopped rt-APC use [Figure 1b]. Between the publications of Leuven-2  and NICE-SUGAR  studies, the population average glucose values by quarter increased gradually from 5.7 to 7.6mmol/L, over the study period. This was associated with reduction in hypoglycemia incidence [Figure 1c].
This descriptive analysis supports our hypothesis. Further analysis will identify key drivers for 'timely' EBM beyond SSC bundle compliance.
Niven DJ, Rubenfield GD, Kramer AA, Stelfox HT: Effect of published scientific evidence on glycemic control in adult intensive care units. JAMA Int Med. 2015, 175 (5): 801-809.
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al: Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013, 41 (2): 580-637.
Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, et al: Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008, 358 (2): 111-124.
Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, et al: Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012, 366 (22): 2055-2064.
Van Den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, et al: Intensive insulin therapy in the medical ICU. N Engl J Med. 2006, 354: 449-461.
The NICE-SUGAR Study Investigators. Hypoglycemia and Risk of Death in Critically Ill Patients. N Engl J Med. 2012, 367: 1108-1118.
About this article
Cite this article
Jones, A., Bond, A., Whiteley, C. et al. IMPACT OF TRIALS ON CLINICAL PRACTICE: INTERVENTIONS IN SEPTIC SHOCK PATIENTS BETWEEN 2005 AND 2013. ICMx 3, A430 (2015) doi:10.1186/2197-425X-3-S1-A430
- Septic Shock
- Septic Shock Patient
- Survive Sepsis Campaign
- Protective Ventilation
- Lung Protective Ventilation